
Retatrutide
An investigational triple-receptor peptide, with listed research presentations, prices and compound specifications.


Explore our range of research peptides with clear vial sizes, current INR prices and availability. Browse the catalogue, check multi-vial savings and confirm your order through WhatsApp.
RESEARCH CATALOGUE

An investigational triple-receptor peptide, with listed research presentations, prices and compound specifications.

A dual GIP/GLP-1 receptor agonist supplied here as a research material; compare listed presentations and specifications.

A two-component peptide research blend; review vial size, constituent amounts and current availability.

Copper tripeptide-1 (GHK-Cu), offered in specified research presentations with detailed compound information.

A dual-component endocrine-signalling research blend; compare vial presentations and composition.

A mitochondrial-derived peptide studied in cellular-stress and metabolic research models.

Bacteriostatic laboratory diluent with 0.9% benzyl alcohol; check container size and compatibility specifications.

A synthetic pentadecapeptide studied primarily in preclinical tissue and gastrointestinal research.

A thymosin-beta-associated research peptide studied in cellular migration and tissue models.

A growth-hormone-releasing-hormone analogue for controlled endocrine-signalling research.
PEPTIDE SCIENCE & RESOURCES
Receptor signalling and metabolic research models.
ILLUSTRATIVE TRENDILLUSTRATIVE COMPARISON · NOT A RANKINGTissue, cell migration and repair-related research models.
ILLUSTRATIVE TRENDILLUSTRATIVE COMPARISON · NOT A RANKINGCellular energy, ageing and mitochondrial research models.
ILLUSTRATIVE TRENDILLUSTRATIVE COMPARISON · NOT A RANKINGEndocrine, receptor and growth-factor research models.
ILLUSTRATIVE TRENDILLUSTRATIVE COMPARISON · NOT A RANKINGEVIDENCE MATRIX
| Study model | Retatrutide | Semaglutide | BPC-157 | TB-500 | GHK-Cu | MOTS-c | SS-31 | NAD+ | CJC+Ipamorelin | Epithalon | Semax | Selank |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Human research | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade |
| Animal models | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade |
| In-vitro studies | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade | Illustrative dot, not an evidence grade |
RESEARCH CATEGORIES
Community polls · Pep-Pedia
Pep-Pedia public poll snapshot · 6 October 2026. Most-selected answers from anonymous self-reports.
| Survey question | Retatrutide | BPC-157 | GHK-Cu | MOTS-c |
|---|---|---|---|---|
| Reported goal | Fat loss90% 1520 / 1696 responses | Recovery/Healing85% 307 / 362 responses | Anti-aging62% 465 / 745 responses | Fat loss31% 142 / 454 responses |
| Self-rated effectiveness | Very effective42% 663 / 1583 responses | Too early to tell31% 103 / 333 responses | Too early to tell46% 312 / 678 responses | Too early to tell39% 159 / 409 responses |
| Frequency · survey only | Once per week70% 989 / 1404 responsesAll responses
| Once daily60% 171 / 287 responsesAll responses
| Once daily79% 468 / 592 responsesAll responses
| 2-3 times per week43% 151 / 349 responsesAll responses
|
| Reported side effects | No side effects24% 518 / 2136 responses | No side effects65% 208 / 318 responses | Injection site reaction41% 280 / 676 responses | No side effects44% 179 / 408 responses |
| Would recommend | Definitely yes59% 816 / 1373 responses | Definitely yes49% 137 / 280 responses | Definitely yes38% 223 / 584 responses | Definitely yes35% 119 / 344 responses |
| Original polls | Retatrutide source ↗ | BPC-157 source ↗ | GHK-Cu source ↗ | MOTS-c source ↗ |
PERSONALIZED CATALOGUE ASSISTANCE
Ask about product availability, laboratory records or documentation. Catalogue enquiries connect to the WhatsApp team.